BRCA1 Reflects Myocardial Adverse Remodeling in Idiopathic Dilated Cardiomyopathy

Nożyński, Jerzy; Konecka-Mrowka, D.; Zakliczyńśki, Michał; Zembala‐Nożyńska, Ewa; Lange, Dariusz; M, Zembala

doi:10.1016/j.transproceed.2015.12.141

Cited by 5 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Follow-up studies reported an association between single nucleotide polymorphisms in BRCA1 -associated protein and myocardial infarction risk in a large Japanese patient cohort with replication in additional Japanese and Taiwanese patient cohorts [ 11 ]. Even in women who do not receive anthracycline-based chemotherapy, BRCA protein deficiency can increase their susceptibility to any form of oxidative stress, whether it is from other types of cancer treatments, early surgical menopause, subclinical ischemia, or endothelial dysfunction from hypertension, hyperlipidemia, diabetes, or insulin resistance (which is known to be increased in the setting of BRCA protein deficiency) [ 12 , 13 , 14 ]. These mechanisms could play a role in the inherently higher risk for heart failure reported in those patients exposed to anthracyclines and those who were chemotherapy naïve.…”

Section: Discussionmentioning

confidence: 99%

An Exploratory Study to Determine Whether BRCA1 and BRCA2 Mutation Carriers Have Higher Risk of Cardiac Toxicity

Sajjad

Fradley

Sun

et al. 2017

Genes

View full text Add to dashboard Cite

Anthracycline-based cardiotoxicity is concerning for women with breast cancer and portends a dose-dependent risk of developing left ventricular dysfunction. Overall, the prevalence of heart failure (HF) is ≈2% of the total US population; however, BRCA-deficient mice have shown increased HF. We evaluated for the inherent risk of HF in women with BRCA mutations to determine whether treatment with anthracycline-based therapy increased this risk. We obtained results on BRCA mutation carriers regarding cancer treatment and HF, identified through the BRCA patient advocacy organization Facing Our Risk for Cancer Empowered (FORCE) and the Moffitt-based Inherited Cancer Registry. In our patient group (232 BRCA1 and 159 BRCA2 patients; 10 with both mutations), 7.7% reported HF, with similar proportions in BRCA1 versus BRCA2 carriers (7.4% and 8.2%, respectively). These proportions are significantly higher than published rates (p < 0.001). There was no statistically significant difference in HF rates comparing anthracycline-treated versus anthracycline-naïve patients however (7.1% vs. 8.3%; p = 0.67). In addition, 9.1% of BRCA1 carriers and 8.2% of BRCA2 carriers reported arrhythmias. BRCA mutation carriers showed increased risk of cardiotoxicity versus the general population and an overall increased risk of cardiotoxicity from anthracycline-based therapy. Our study supports data that BRCA carriers have increased non-cancer mortality from cardiotoxicity. A prospective trial to determine HF and conduction abnormalities in this population is warranted.

show abstract

Section: Discussionmentioning

confidence: 99%

An Exploratory Study to Determine Whether BRCA1 and BRCA2 Mutation Carriers Have Higher Risk of Cardiac Toxicity

Sajjad

Fradley

Sun

et al. 2017

Genes

View full text Add to dashboard Cite

show abstract

“…Implantation of biomaterials is intended to assess, augment, or replace the biological function of the host tissue, which is widely done nowadays in a variety of medical applications including glucose biosensors, heart valves, cardiac pacemakers, different types of implants, stents, catheters, and so on. Nevertheless, all materials introduced into the human body may trigger a series of undesired host responses, encompassing injury, blood–material interactions, acute inflammation, chronic inflammation, granulation tissue development, foreign body reaction (FBR), and fibrous encapsulation .…”

Section: Introductionmentioning

confidence: 99%

Host Responses to Biomaterials and Anti‐Inflammatory Design—a Brief Review

Zhou

Groth

2018

Macromolecular Bioscience

105

View full text Add to dashboard Cite

Host responses toward foreign implants that lead to chronic inflammation and fibrosis may result in failure of the biomedical device. To solve these problems, first a better understanding of the biomaterial-induced host reactions including protein adsorption, leukocyte activation, inflammatory and fibrotic responses to biomaterials is required; second an improved design of biomaterial surfaces is needed that results in an appropriate host response, causing less inflammatory response, and supporting tissue regeneration. Hence, this review provides a brief overview on the host response to implants, as well as in vitro models to study inflammatory and fibrotic responses to biomaterials to predict the clinical outcome of implantation. Moreover, the review highlights anti-inflammatory strategies to improve the biocompatibility of implants, which contain the modification of physicochemical surface properties of materials as well as the immobilization of anti-inflammatory reagents and bioactive molecules on biomaterials.

show abstract

Left ventricular global longitudinal strain is worse in BRCA mutation positive breast cancer patients prior to cancer treatment and premature menopause

Lin,

LeVee,

Cao

et al. 2024

Breast Cancer Res Treat

View full text Add to dashboard Cite

BRCA1 Reflects Myocardial Adverse Remodeling in Idiopathic Dilated Cardiomyopathy

Cited by 5 publications

References 18 publications

An Exploratory Study to Determine Whether BRCA1 and BRCA2 Mutation Carriers Have Higher Risk of Cardiac Toxicity

An Exploratory Study to Determine Whether BRCA1 and BRCA2 Mutation Carriers Have Higher Risk of Cardiac Toxicity

Host Responses to Biomaterials and Anti‐Inflammatory Design—a Brief Review

Left ventricular global longitudinal strain is worse in BRCA mutation positive breast cancer patients prior to cancer treatment and premature menopause

Contact Info

Product

Resources

About